Palisade Bio Begins Clinical Trial for Ulcerative Colitis

The Denver-based company has administered its first dose of the PALI-2108 prodrug to a patient in the new study.

Updated on Oct. 28, 2026 in Healthcare

Isometric editorial illustration depicting clean, empty scientific vials on a lab bench, representing pharmaceutical clinical research.
Palisade Bio has begun its ASCENTRA-UC clinical trial in the United States, administering the first dose of its oral PALI-2108 drug for ulcerative colitis. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies prioritize developing new oral therapies for chronic inflammatory diseases?

Palisade Bio officially launched its ASCENTRA-UC clinical trial by dosing the first patient with its oral PDE4 inhibitor, PALI-2108. The study is designed to evaluate the drug as a treatment for ulcerative colitis.

Why it matters

The trial seeks to determine if the drug can offer clinical benefits while overcoming previous tolerability issues associated with systemic PDE4 inhibitors. Success in this study could validate a new approach for managing this chronic condition.

The study aims to enroll 204 patients across 115 total planned global clinical sites. Participants will receive either 15 mg or 30 mg doses of PALI-2108 compared to a placebo.

The players

Palisade Bio

This is a biopharmaceutical company headquartered in Denver that focuses on developing oral therapeutics for inflammatory and fibrotic diseases.

The details

The ASCENTRA-UC trial utilizes a randomized, double-blind, placebo-controlled design to test the once-daily oral drug. Palisade Bio has already activated 29 of 30 planned clinical sites within the United States.

Timeline

  1. The first patient was dosed in the ASCENTRA-UC trial on October 28, 2026.

  2. Topline induction results for the 12-week study period are expected in the fourth quarter of 2027.

Market Landscape

The study marks a shift from systemic PDE4 inhibition toward gut-activated prodrugs designed to improve patient tolerability. This move positions the firm to challenge existing treatment paradigms within the competitive landscape for ulcerative colitis therapies.

The clinical trial currently remains in the testing phase, meaning PALI-2108 is not available for prescription or purchase by patients. The long-term impact on healthcare options will depend entirely on the results expected in 2027.

The takeaway

Patients currently managing ulcerative colitis should continue consulting with their doctors regarding established care protocols. This trial serves as a reminder that experimental treatments undergo years of rigorous testing before reaching the clinic.

Further reading

For more information on ongoing medical developments in the region, visit the Healthcare section.

More information

For official updates on the clinical study, visit Palisade Bio company information.

Source note: This article includes information reported by The Manila times.

Live Poll

Should pharmaceutical companies prioritize developing new oral therapies for chronic inflammatory diseases?